LOS ANGELES, July 20, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) -- Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today ...
OAKLAND, Calif.--(BUSINESS WIRE)--Shares of Enochian Biosciences, Inc. plunged 36% on May 25, 2022 after its co-founder and largest shareholder, Dr. Serhat Gumrukçu, was arrested and charged by the ...
LOS ANGELES, Oct. 18, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) − Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today ...
SAN DIEGO--(BUSINESS WIRE)--The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Enochian Biosciences Inc. (NASDAQ: ENOB) securities between January 17, 2018 and ...
LOS ANGELES, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Enochian Biosciences, a company focused on gene-modified cellular therapy in infectious disease and cancer, announces the expansion of its infectious ...
Electronic trading platform E-Trade has reportedly blocked customers from buying Enochian Biosciences stock after the biotech announced the Food and Drug Administration had accepted its Pre-IND ...
Enochian Biosciences Inc (NASDAQ:ENOB) shares are trading lower Wednesday after Hindenburg Research issued a bearish report on the company. Hindenburg noted that Gumrukcu is not only the co-founder of ...
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. Enochian BioSciences Inc. (NASDAQ: ENOB) shares more than ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback